Published in Biomacromolecules on September 13, 2016
Heparin-Mimicking Polymers: Synthesis and Biological Applications. Biomacromolecules (2016) 0.75
Cutaneous wound healing. N Engl J Med (1999) 19.12
Regulation of wound healing by growth factors and cytokines. Physiol Rev (2003) 9.82
Fibroblast growth factors. Genome Biol (2001) 7.32
Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen (2009) 7.29
Polymeric system for dual growth factor delivery. Nat Biotechnol (2001) 7.20
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Biological roles of fibroblast growth factor-2. Endocr Rev (1997) 3.57
Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A (1986) 3.42
Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol (1992) 3.41
Structural basis for FGF receptor dimerization and activation. Cell (1999) 3.19
Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol (1998) 3.12
Heparin protects basic and acidic FGF from inactivation. J Cell Physiol (1986) 3.09
Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med (1988) 3.03
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2010) 2.70
Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol (1997) 2.17
Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis (2001) 2.14
An in vitro model of angiogenesis: basic features. Angiogenesis (1999) 1.71
Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J Biol Chem (1992) 1.53
Nationwide Trends of Hospital Admission and Outcomes Among Critical Limb Ischemia Patients: From 2003-2011. J Am Coll Cardiol (2016) 1.50
Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat Chem (2011) 1.50
Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors (1996) 1.50
Controlled and modulated release of basic fibroblast growth factor. Biomaterials (1991) 1.48
Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing. Biomaterials (2015) 1.41
Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol (1999) 1.34
Heparinase inhibits neovascularization. Proc Natl Acad Sci U S A (1994) 1.19
The role of growth factors in wound healing. J Trauma (1996) 1.18
Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol (2006) 1.18
The fate of intravenously administered bFGF and the effect of heparin. Growth Factors (1989) 1.17
Trehalose glycopolymers for stabilization of protein conjugates to environmental stressors. J Am Chem Soc (2012) 1.14
Glycosaminoglycan mimetic biomaterials. 4. Synthesis of sulfated lactose-based glycopolymers that exhibit anticoagulant activity. Biomacromolecules (2002) 1.06
Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J Am Chem Soc (2014) 1.05
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol (1999) 1.04
Growth factor release from tissue engineering scaffolds. J Pharm Pharmacol (2001) 1.03
Covalently attached FGF-2 to three-dimensional polyamide nanofibrillar surfaces demonstrates enhanced biological stability and activity. Mol Cell Biochem (2007) 1.00
The costs of diabetic foot: the economic case for the limb salvage team. J Am Podiatr Med Assoc (2010) 0.99
A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat Chem (2013) 0.99
Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care (2012) 0.98
Smart hybrid materials by conjugation of responsive polymers to biomacromolecules. Nat Mater (2014) 0.97
Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle) (2015) 0.97
Site-selective protein-modification chemistry for basic biology and drug development. Nat Chem (2015) 0.96
Effect of single growth factor and growth factor combinations on differentiation of neural stem cells. J Korean Neurosurg Soc (2008) 0.94
Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care (1995) 0.93
Heparin in the treatment of burns: a review. Burns (2001) 0.92
A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival. J Neurochem (2005) 0.91
Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol (1992) 0.89
Probing fibroblast growth factor dimerization and role of heparin-like glycosaminoglycans in modulating dimerization and signaling. J Biol Chem (2001) 0.89
Properties and biological interactions of polyurethane anionomers: effect of sulfonate incorporation. J Biomed Mater Res (1989) 0.86
Universal (switchable) RAFT agents. J Am Chem Soc (2009) 0.86
Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization. Biomaterials (1984) 0.86
Heparin and heparan sulfate: analyzing structure and microheterogeneity. Handb Exp Pharmacol (2012) 0.86
Uses of the in vitro endothelial-fibroblast organotypic co-culture assay in angiogenesis research. Biochem Soc Trans (2011) 0.85
Structure-activity relationships of heparin-mimicking compounds in induction of bFGF release from extracellular matrix and inhibition of smooth muscle cell proliferation and heparanase activity. J Cell Physiol (2002) 0.85
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. Int Wound J (2013) 0.85
Inhibition of human angiogenesis with heparin and hydrocortisone. Angiogenesis (2001) 0.85
Heparin stabilizes FGF-2 and modulates striatal precursor cell behavior in response to EGF. Exp Neurol (2004) 0.83
Growth factor binding on heparin mimetic peptide nanofibers. Biomacromolecules (2012) 0.83
Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. Eur J Cell Biol (1998) 0.82
Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2. Biochem J (2000) 0.81
Effects of FGF receptor peptide agonists on animal behavior under normal and pathological conditions. Neurosci Res (2010) 0.80
Hydrogels for therapeutic cardiovascular angiogenesis. Adv Drug Deliv Rev (2015) 0.80
A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacology (2006) 0.80
Well-defined biohybrids using reversible-deactivation radical polymerization procedures. J Control Release (2014) 0.80
Poly(vinyl sulfonate) Facilitates bFGF-Induced Cell Proliferation. Biomacromolecules (2015) 0.78
Management of thrombotic and cardiovascular disorders in the new millenium. Clin Appl Thromb Hemost (2003) 0.78
Conjugation of basic fibroblast growth factor on a heparin gradient for regulating the migration of different types of cells. Bioconjug Chem (2013) 0.76
Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor. Chin Med J (Engl) (2002) 0.76
Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs (2008) 0.76
Dramatically increased pH and temperature stability of chymotrypsin using dual block polymer-based protein engineering. Biomacromolecules (2014) 0.76
Socioeconomic Status and Outcomes After Burn Injury. J Burn Care Res (2015) 0.76
Synthesis and non-thrombogenicity of heparinoid polyurethaneureas. Biomaterials (1992) 0.76
Investigating the Impact of Polymer Functional Groups on the Stability and Activity of Lysozyme-Polymer Conjugates. Biomacromolecules (2016) 0.76
Poly(vinyl sulfonate) Facilitates bFGF-Induced Cell Proliferation. Biomacromolecules (2015) 0.78